about
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsClinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variantsEffect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards.Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome.Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.Association of thymidylate synthase polymorphisms with acute pancreatitis and/or peripheral neuropathy in HIV-infected patients on stavudine-based therapyAssociation of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy.Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients.Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels.Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain.Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients.Sarcoidosis presenting as multiple pulmonary nodules and nephrotic syndrome.Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS.Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients.Drug safety profile of integrase strand transfer inhibitors.An update on the pharmacological strategies in the treatment of HIV-1-associated adipose redistribution syndromes.Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).Effects of docosahexanoic acid on metabolic and fat parameters in HIV-infected patients on cART: A randomized, double-blind, placebo-controlled study.Drug therapies for HIV-related metabolic disorders.Switching antiretroviral regimes for the treatment of HIV: safety implications.Spermatozoa from normozoospermic fertile and infertile individuals convey a distinct miRNA cargo.A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach.Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recovery.Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients.HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers.ART regimes and fat: the healing hand wielding the sword.Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.Atazanavir dose reduction: one size does not fit all.Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicity.HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma.Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients.IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals.
P50
Q24674939-6AC89843-A767-46D9-94F2-919939E7F4DAQ33267347-2A7C77DC-8218-4ADC-912C-7092152CABBCQ33404251-BE9CE115-C645-491F-A1E4-41BFB91D5CF0Q33564972-F322DFDE-5EE3-4380-946F-DC953B6FCF4DQ33749881-2F6E2F27-9560-4328-BEA2-74C9ADC49B6EQ33982131-B8F15EA8-A409-4459-BFF6-38DBEDDA83B0Q34596899-B79D2A0E-7C4D-444B-83AB-E0D91E4287F8Q34612023-F6C1E7E2-8D9F-4FFE-A579-2E8A72406D95Q34737674-80DD088C-597A-45B3-9B11-5C61C026A302Q34806335-2172C1B0-E1C2-4C1A-98AC-3C9D2527524CQ35270923-05B38DA7-109D-4DBF-957B-2E80A3060FF8Q35806266-20A3E0BA-5769-4CAB-B759-29426E4D8E61Q35866999-7C0EEB1B-108C-4136-BE70-BA65BA082DBEQ35980035-D384F6D9-9BA7-4015-8CCF-CC16CE20B88EQ36018931-65E8D1C5-75D2-4B15-85D1-D6B7F93CF793Q36375948-59AD72B8-4597-4D3C-821F-1714711E86B2Q36707469-7C33E5F9-9A15-49B7-9C40-D976EACD8F33Q37945715-20C60585-D8BF-4456-92BA-0DE86B40C7B6Q37999051-50C767E2-EC0C-4125-ABDC-35D0A8F3E079Q38091148-56E44A50-A5F7-4F80-A02B-24317E426FF6Q38164430-D8D5D72B-B6DD-4191-AE80-04C19220AE54Q38193524-3087C501-421C-4FEF-8407-DBC2C4BB91BDQ38220651-0CFEEE3E-4314-418C-A786-A23A5CCB9051Q38225483-954CC859-BFE8-463D-9E92-94F02E031FC2Q38374994-C1456E31-79CF-4F3E-8474-318693307449Q38837421-BF5EBFF4-0136-444A-A32E-117060E29DC4Q38879406-C01B9749-AC58-45A9-9DA3-FF113B5A963FQ39347084-D2CBCDFE-6641-4AA6-AEE4-6E27A7413009Q39408333-18AB6F14-A347-4C3B-A022-D1F02632452AQ40060299-7B001052-0BF7-46B9-B049-47F73AACEB73Q40278234-8DF85ED1-5107-487C-9677-92A530106596Q40364181-9ECEA7F1-28AC-4FD9-91AB-78A87F9245CFQ40406168-9E88F5D6-2A57-484D-A044-40685522C3BCQ40463477-0A01EB0A-04F2-4E9F-9BA3-F21788C54AF9Q40593936-6EEB92C0-FA79-49D3-A6E7-5E29E38213CDQ40596052-E2BBC20B-CDD7-4E31-A77E-4AC81DDA6721Q41276695-D1F6C510-FDDE-4A52-BABA-C0ADC03BFA8FQ41325832-1D11825B-3E8B-454E-B259-D73D4E8588C6Q41380838-6C288EDD-D2D7-4F5E-8483-205EF5D89803Q41498445-007E3EBD-6F64-486D-8857-B682A596409A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesc Vidal
@ast
Francesc Vidal
@en
Francesc Vidal
@es
Francesc Vidal
@nl
Francesc Vidal
@sl
type
label
Francesc Vidal
@ast
Francesc Vidal
@en
Francesc Vidal
@es
Francesc Vidal
@nl
Francesc Vidal
@sl
prefLabel
Francesc Vidal
@ast
Francesc Vidal
@en
Francesc Vidal
@es
Francesc Vidal
@nl
Francesc Vidal
@sl
P108
P106
P1153
35517147900
P21
P31
P496
0000-0002-6692-6186